HC Wainwright Comments on Korro Bio FY2026 Earnings

Korro Bio, Inc. (NASDAQ:KRRO) – Analysts at HC Wainwright issued their FY2026 earnings estimates for Korro Bio in a research report issued on Thursday, May 8th. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($8.32) for the year. HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio’s Q4 2026 earnings at ($2.17) EPS.

Other research analysts also recently issued reports about the company. Cantor Fitzgerald raised Korro Bio to a “strong-buy” rating in a research report on Tuesday, April 29th. Chardan Capital began coverage on shares of Korro Bio in a research note on Wednesday, April 16th. They set a “buy” rating and a $25.00 target price for the company. Oppenheimer started coverage on shares of Korro Bio in a research report on Friday, January 10th. They issued an “outperform” rating and a $155.00 price target on the stock. Finally, Royal Bank of Canada cut their price objective on shares of Korro Bio from $105.00 to $95.00 and set an “outperform” rating for the company in a research report on Wednesday, March 19th. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $112.75.

Korro Bio Stock Performance

NASDAQ KRRO opened at $15.56 on Friday. The stock has a 50-day simple moving average of $17.78 and a 200 day simple moving average of $34.55. Korro Bio has a twelve month low of $11.13 and a twelve month high of $98.00. The stock has a market capitalization of $146.12 million, a PE ratio of -1.65 and a beta of 2.66.

Korro Bio (NASDAQ:KRRO) last released its earnings results on Wednesday, May 7th. The company reported ($2.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.60) by $0.11. The firm had revenue of $2.55 million for the quarter, compared to analyst estimates of $0.13 million.

Institutional Trading of Korro Bio

Several institutional investors have recently made changes to their positions in KRRO. AlphaQuest LLC grew its stake in shares of Korro Bio by 23.2% in the 4th quarter. AlphaQuest LLC now owns 2,189 shares of the company’s stock valued at $83,000 after purchasing an additional 412 shares during the period. Bank of New York Mellon Corp grew its position in Korro Bio by 3.0% in the fourth quarter. Bank of New York Mellon Corp now owns 14,788 shares of the company’s stock valued at $563,000 after acquiring an additional 435 shares during the period. Bank of America Corp DE raised its stake in Korro Bio by 9.0% during the fourth quarter. Bank of America Corp DE now owns 7,037 shares of the company’s stock worth $268,000 after acquiring an additional 581 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Korro Bio by 7.8% during the fourth quarter. Rhumbline Advisers now owns 9,602 shares of the company’s stock valued at $366,000 after acquiring an additional 691 shares during the period. Finally, Blair William & Co. IL boosted its stake in shares of Korro Bio by 5.7% in the 4th quarter. Blair William & Co. IL now owns 12,895 shares of the company’s stock valued at $491,000 after purchasing an additional 695 shares in the last quarter. 13.18% of the stock is currently owned by institutional investors and hedge funds.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).